Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [17]
- Comments [0]
- Validations
- Immunocytochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA026980 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA026980, RRID:AB_10602801
- Product name
- Anti-CMTM6
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human CMTM6, Gene description: CKLF-like MARVEL transmembrane domain containing 6, Alternative Gene Names: CKLFSF6, FLJ20396, Validated applications: ICC, IHC, WB, Uniprot ID: Q9NX76, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.2 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation
CMTM6 as a potential therapy target is associated with immunological tumor microenvironment and can promote migration and invasion in pancreatic adenocarcinoma
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity
Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis
CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer
Prostasin regulates PD-L1 expression in human lung cancer cells
HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer
Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer
Co-Expression with Membrane CMTM6/4 on Tumor Epithelium Enhances the Prediction Value of PD-L1 on Anti-PD-1/L1 Therapeutic Efficacy in Gastric Adenocarcinoma
High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence
CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma.
CMTM6 drives cisplatin resistance by regulating Wnt signaling through ENO-1/AKT/GSK3β axis
Antioxidant functions of DHHC3 suppress anti-cancer drug activities
Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Xu X, Xie T, Zhou M, Sun Y, Wang F, Tian Y, Chen Z, Xie Y, Wu R, Cen X, Zhou J, Hou T, Zhang L, Huang C, Zhao Q, Wang D, Xia H
Nature Communications 2024;15(1)
Nature Communications 2024;15(1)
CMTM6 as a potential therapy target is associated with immunological tumor microenvironment and can promote migration and invasion in pancreatic adenocarcinoma
Gao H, Yin J, Guan X, Zhang S, Peng S, Liu X, Xing F
Functional & Integrative Genomics 2023;23(4)
Functional & Integrative Genomics 2023;23(4)
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Xing F, Gao H, Chen G, Sun L, Sun J, Qiao X, Xue J, Liu C
Molecular Cancer 2023;22(1)
Molecular Cancer 2023;22(1)
Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity
Wang H, Fan Y, Chen W, Lv Z, Wu S, Xuan Y, Wang C, Lu Y, Guo T, Shen D, Zhang F, Huang Q, Gao Y, Li H, Ma X, Wang B, Huang Y, Zhang X
OncoImmunology 2022;11(1)
OncoImmunology 2022;11(1)
Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis
Tang T, Huang X, Zhang G, Lu M, Hong Z, Wang M, Huang J, Zhi X, Liang T
Journal for ImmunoTherapy of Cancer 2022;10(3):e004129
Journal for ImmunoTherapy of Cancer 2022;10(3):e004129
CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer
Peng Q, Wang C, Chen H, Zhang R, Pan Z, Lu Z, Wang G, Yue X, Huang W, Liu R
Journal for ImmunoTherapy of Cancer 2021;9(2):e001638
Journal for ImmunoTherapy of Cancer 2021;9(2):e001638
Prostasin regulates PD-L1 expression in human lung cancer cells
Chen L, Chai J, Liu B, Strutt T, McKinstry K, Chai K
Bioscience Reports 2021;41(7)
Bioscience Reports 2021;41(7)
HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer
Liu Y, Li X, Zhang H, Zhang M, Wei Y
Oncogene 2021;40(12):2230-2242
Oncogene 2021;40(12):2230-2242
Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer
Xiao M, Hasmim M, Lequeux A, Moer K, Tan T, Gilles C, Hollier B, Thiery J, Berchem G, Janji B, Noman M
Cancers 2021;13(5):1165
Cancers 2021;13(5):1165
Co-Expression with Membrane CMTM6/4 on Tumor Epithelium Enhances the Prediction Value of PD-L1 on Anti-PD-1/L1 Therapeutic Efficacy in Gastric Adenocarcinoma
Wang Z, Peng Z, Liu Q, Guo Z, Menatola M, Su J, Li T, Ge Q, Wang P, Shen L, Jin R
Cancers 2021;13(20):5175
Cancers 2021;13(20):5175
High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence
Muranushi R, Araki K, Yokobori T, Chingunjav B, Hoshino K, Dolgormaa G, Hagiwara K, Yamanaka T, Ishii N, Tsukagoshi M, Igarashi T, Watanabe A, Kubo N, Harimoto N, Shimoda Y, Sano R, Oyama T, Saeki H, Shirabe K
Cancer Science 2021;112(8):3314-3323
Cancer Science 2021;112(8):3314-3323
CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma.
Yugawa K, Itoh S, Yoshizumi T, Iseda N, Tomiyama T, Morinaga A, Toshima T, Harada N, Kohashi K, Oda Y, Mori M
Hepatology communications 2021 Feb;5(2):334-348
Hepatology communications 2021 Feb;5(2):334-348
CMTM6 drives cisplatin resistance by regulating Wnt signaling through ENO-1/AKT/GSK3β axis
Mohapatra P, Shriwas O, Mohanty S, Ghosh A, Smita S, Kaushik S, Arya R, Rath R, Das Majumdar S, Muduly D, Raghav S, Nanda R, Dash R
JCI Insight 2021
JCI Insight 2021
Antioxidant functions of DHHC3 suppress anti-cancer drug activities
Sharma C, Yang W, Steen H, Freeman M, Hemler M
Cellular and Molecular Life Sciences 2020;78(5):2341-2353
Cellular and Molecular Life Sciences 2020;78(5):2341-2353
Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers
Takeuchi H, Konnai S, Maekawa N, Minato E, Ichikawa Y, Kobayashi A, Okagawa T, Murata S, Ohashi K
Frontiers in Veterinary Science 2020;7
Frontiers in Veterinary Science 2020;7
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Mezzadra R, Sun C, Jae L, Gomez-Eerland R, de Vries E, Wu W, Logtenberg M, Slagter M, Rozeman E, Hofland I, Broeks A, Horlings H, Wessels L, Blank C, Xiao Y, Heck A, Borst J, Brummelkamp T, Schumacher T
Nature 2017;549(7670):106-110
Nature 2017;549(7670):106-110
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Burr M, Sparbier C, Chan Y, Williamson J, Woods K, Beavis P, Lam E, Henderson M, Bell C, Stolzenburg S, Gilan O, Bloor S, Noori T, Morgens D, Bassik M, Neeson P, Behren A, Darcy P, Dawson S, Voskoboinik I, Trapani J, Cebon J, Lehner P, Dawson M
Nature 2017;549(7670):101-105
Nature 2017;549(7670):101-105
No comments: Submit comment
Supportive validation
- Submitted by
- Atlas Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent staining of human cell line A-431 shows localization to cytosol & intermediate filaments.
- Sample type
- Human
